Please provide your email address to receive an email when new articles are posted on . A Bay Area biopharmaceutical firm has announced positive results from its phase 1 clinical trial in healthy ...

There are currently no FDA-approved treatments for CIAS, a disabling feature of the disease that includes impaired attention, memory, and executive function. The Food and Drug Administration (FDA) has ...

DelveInsight’s PDE4 Inhibitor Market Insights report includes a comprehensive understanding of current treatment practices, emerging PDE4 inhibitors, market share of individual therapies, and current ...

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the initiation of a Phase 2 double-blind, placebo-controlled study of its transdermal formulation of ...

Chiesi Group announces that it has successfully completed a Phase I trial of its inhaled PDE4 (phosphodiesterase 4) inhibitor, denoted CHF 6001, a new chemical entity developed for the treatment of ...